MedTrace Logo

TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.

NCT07602140 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-22

No results posted yet for this study

Summary

This study is a multicenter, single-arm prospective clinical trial designed to evaluate the efficacy of TACE combined with thermal ablation, antibody-drug conjugates, immune checkpoint inhibitors, and first-line chemotherapy for the treatment of HER2 - highly expressing gastric cancer with liver metastases.

Conditions

  • Gastric Cancer With Liver Metastases

Interventions

OTHER

TACE combined with thermal ablation

The decision to perform transarterial chemoembolization (TACE) and/or thermal ablation is based on the blood supply, size, and number of liver metastases as determined by imaging examinations. Interventional therapy is repeated every two cycles, and TACE and/or thermal ablation therapy are selected based on the blood supply, location, size and number of liver metastases.

DRUG

Targeted Therapy

Disitamab Vedotin For Injection: 2.5 mg/kg, day 1, IV drip , Q3W.

DRUG

Immunotherapy

Sintilimab : 200mg , d1 , ivdrip , q3w

DRUG

Chemotherapy

S-1 : 40-60 mg/dose, orally, twice daily (bid), daily (days 1-14) , every 3 weeks (q3w).

Sponsors & Collaborators

  • Shandong Provincial Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2028-08-01
Completion
2029-08-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07602140 on ClinicalTrials.gov